Neurogene
NGNE
36 hedge funds and large institutions have $14.3M invested in Neurogene in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 8 closing their positions.
36% more capital invested
Capital invested by funds: $10.5M → $14.3M (+$3.8M)
0.26% more ownership
Funds ownership: 1.76% → 2.02% (+0.26%)
8% less funds holding
Funds holding: 39 → 36 (-3)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$873K |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$706K |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$546K |
| 4 |
AFA
Alta Fundamental Advisers
New York
|
+$73.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$39.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$137K |
| 2 |
BlackRock
New York
|
-$66K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$52.5K |
| 4 |
Two Sigma Advisers
New York
|
-$40.7K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
-$28K |
NGNE Hedge Fund Activity: Q2 2023 in Review
36 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2023, worth a combined $14.3M — up 36% from $10.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NGNE and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Redmile Group, adding an estimated $873K. The largest seller was Millennium Management, cutting an estimated $137K.
- 36 institutional investors held Neurogene (NGNE) as of Q2 2023, down from 39 in Q1 2023.
- Funds reported $14.3M of Neurogene stock for Q2 2023, up 36% quarter-over-quarter.
- 5 funds opened new Neurogene positions in Q2 2023 and 8 closed out, a net change of -3 holders.
- The largest Neurogene buyer in Q2 2023 was Redmile Group, an estimated $873K added.
- The largest Neurogene seller in Q2 2023 was Millennium Management, an estimated $137K sold.
Based on aggregated 13F filings for Q2 2023.